Despite tremendous progress in basic science, there have been no new breakthroughs in the treatment of many CNS diseases.

CNS quantitative systems pharmacology is based on the realization that human pathology is driven by a network imbalance rather than deficits at a single target or gene. Computer-based modeling of biophysically realistic neuronal network circuits calibrated with human imaging and clinical data is a translational tool to assess the outcome of therapeutic interventions in complex brain circuits. The company provides insights into the systemic behavior at each R&D stage in high impact decision processes. We provide model based decision support and knowledge support from target validation to personalized medicine for

Schizophrenia (PANSS Total, PANSS Negative, Cognitive Impairment)
Antipsychotic-induced side effects (Extra-pyramidal symptoms, Akathisia, Prolactin increase)
Alzheimer’s disease (Cognition, Neuropsychiatric symptoms and Beta-amyloid dynamics)
Parkinson’s disease (Rigidity-bradykinesia, Tremor, L-DOPA induced dyskinesia)
Our modeling addresses the following key questions

Target validation
Clinical candidate selection
Support rationally designed multipharmacology drug discovery projects
Rational support for combination therapy
Clinical biomarker selection for functional target engagement
Dosing guidance
Clinical study design especially with comedications and genotypes
Competitive analysis
Clinical responder analysis